Clinical characteristics of patients with histologic BOOP and control subjects
Characteristic . | BOOP patients, N = 49 . | Control subjects, N = 161 . | P* . |
|---|---|---|---|
| Mean age at HSC transplantation, y | 30.1 | 30.6 | .79 |
| Men, n (%) | 38 (78) | 105 (65) | .09 |
| Diagnosis, n (%) | .08 | ||
| Acute lymphocytic leukemia | 11 (22) | 24 (15) | |
| Acute nonlymphocytic leukemia (ANL) | 20 (41) | 40 (25) | |
| Chronic myelogenous leukemia (CML) | 11 (22) | 48 (30) | |
| Lymphoma | 3 (6) | 10 (6) | |
| Myelodysplastic syndrome (MDS) | 3 (6) | 15 (9) | |
| Aplastic anemia | 0 (0) | 16 (10) | |
| Other† | 1 (3) | 8 (5) | |
| Disease activity, n (%) | .39 | ||
| Remission | 17 (35) | 38 (24) | |
| Relapse | 17 (35) | 36 (22) | |
| Acute-phase CML | 2 (4) | 11 (7) | |
| Chronic-phase CML | 8 (16) | 36 (22) | |
| De novo‡ | 1 (2) | 3 (2) | |
| Unknown | 4 (8) | 37 (23) | |
| HLA matching, n (%) | .68 | ||
| Matched related | 29 (59) | 100 (62) | |
| Mismatched related | 5 (10) | 21 (13) | |
| Unrelated | 15 (31) | 40 (25) | |
| Stem cell source, n (%) | .91 | ||
| Bone marrow | 45 (92) | 150 (93) | |
| Peripheral blood | 3 (6) | 9 (6) | |
| Cord blood | 1 (2) | 2 (1) | |
| Preparative regimen, §n (%) | .004 | ||
| Cyclophosphamide | 0 | 5 (3) | |
| Cyclophosphamide, busulfan | 4 (8) | 27 (17) | |
| Cyclophosphamide, buffy coat¶ | 0 | 4 (3) | |
| Cyclophosphamide, ATG | 0 | 6 (4) | |
| Cyclophosphamide, TBI | 8 (17) | 9 (6) | |
| Cyclophosphamide, F-TBI | 12 (26) | 53 (34) | |
| Cyclophosphamide, H-TBI | 17 (35) | 37 (24) | |
| Thiotepa-containing regimen | 4 (9) | 2 (1) | |
| Busulfan, H-TBI | 1 (2) | 6 (4) | |
| VP-16, H-TBI | 0 (0) | 4 (3) | |
| Other | 1 (2) | 2 (1) | |
| GVHD prophylaxis,∥n (%) | .81 | ||
| Cyclosporin | 6 (12) | 19 (13) | |
| Methotrexate | 9 (19) | 22 (15) | |
| Cyclosporin, methotrexate | 27 (56) | 91 (61) | |
| Other | 6 (12) | 17 (11) | |
| Recipient CMV antibody-positive,** n (%) | 23 (55) | 71 (51) | .71 |
| Donor CMV antibody-positive,** n (%) | 20 (48) | 63 (45) | .79 |
| Survival, n (%) | .05 | ||
| 1-year survival | 27 (55) | 95 (59) | |
| 5-year survival | 15 (31) | 72 (45) |
Characteristic . | BOOP patients, N = 49 . | Control subjects, N = 161 . | P* . |
|---|---|---|---|
| Mean age at HSC transplantation, y | 30.1 | 30.6 | .79 |
| Men, n (%) | 38 (78) | 105 (65) | .09 |
| Diagnosis, n (%) | .08 | ||
| Acute lymphocytic leukemia | 11 (22) | 24 (15) | |
| Acute nonlymphocytic leukemia (ANL) | 20 (41) | 40 (25) | |
| Chronic myelogenous leukemia (CML) | 11 (22) | 48 (30) | |
| Lymphoma | 3 (6) | 10 (6) | |
| Myelodysplastic syndrome (MDS) | 3 (6) | 15 (9) | |
| Aplastic anemia | 0 (0) | 16 (10) | |
| Other† | 1 (3) | 8 (5) | |
| Disease activity, n (%) | .39 | ||
| Remission | 17 (35) | 38 (24) | |
| Relapse | 17 (35) | 36 (22) | |
| Acute-phase CML | 2 (4) | 11 (7) | |
| Chronic-phase CML | 8 (16) | 36 (22) | |
| De novo‡ | 1 (2) | 3 (2) | |
| Unknown | 4 (8) | 37 (23) | |
| HLA matching, n (%) | .68 | ||
| Matched related | 29 (59) | 100 (62) | |
| Mismatched related | 5 (10) | 21 (13) | |
| Unrelated | 15 (31) | 40 (25) | |
| Stem cell source, n (%) | .91 | ||
| Bone marrow | 45 (92) | 150 (93) | |
| Peripheral blood | 3 (6) | 9 (6) | |
| Cord blood | 1 (2) | 2 (1) | |
| Preparative regimen, §n (%) | .004 | ||
| Cyclophosphamide | 0 | 5 (3) | |
| Cyclophosphamide, busulfan | 4 (8) | 27 (17) | |
| Cyclophosphamide, buffy coat¶ | 0 | 4 (3) | |
| Cyclophosphamide, ATG | 0 | 6 (4) | |
| Cyclophosphamide, TBI | 8 (17) | 9 (6) | |
| Cyclophosphamide, F-TBI | 12 (26) | 53 (34) | |
| Cyclophosphamide, H-TBI | 17 (35) | 37 (24) | |
| Thiotepa-containing regimen | 4 (9) | 2 (1) | |
| Busulfan, H-TBI | 1 (2) | 6 (4) | |
| VP-16, H-TBI | 0 (0) | 4 (3) | |
| Other | 1 (2) | 2 (1) | |
| GVHD prophylaxis,∥n (%) | .81 | ||
| Cyclosporin | 6 (12) | 19 (13) | |
| Methotrexate | 9 (19) | 22 (15) | |
| Cyclosporin, methotrexate | 27 (56) | 91 (61) | |
| Other | 6 (12) | 17 (11) | |
| Recipient CMV antibody-positive,** n (%) | 23 (55) | 71 (51) | .71 |
| Donor CMV antibody-positive,** n (%) | 20 (48) | 63 (45) | .79 |
| Survival, n (%) | .05 | ||
| 1-year survival | 27 (55) | 95 (59) | |
| 5-year survival | 15 (31) | 72 (45) |
HLA indicates human lymphocyte antigen; ATG, antithymocyte globulin; TBI, total body irradiation; F-TBI, fractionated TBI; and H-TBI, hyperfractionated TBI.
P value from conditional logistic regression.
Other diagnoses include the following: paroxysmal nocturnal hemoglobinuria, multiple myeloma, Ewing sarcoma.
De novo indicates acute leukemia without prior induction chemotherapy.
Missing data for 2 case and 6 control subjects.
Buffy coat indicates administration of nonmobilized peripheral blood cells on days 1 through 4 after bone marrow infusion.
Missing data for 1 case and 12 control patients.
Missing data for 7 cases and 22 control patients.